Prosecution Insights
Last updated: November 04, 2026

The DNA Company Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

The DNA Company Inc. is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's prosecution profile is characterized by its simplicity, with only 1 distinct examiner and 1 distinct art unit involved. This indicates that the current patent filings are concentrated within a specific technical niche that does not span multiple examination groups at the patent office.

The busiest examiner, BAILEY, STEVEN WILLIAM, is currently handling 1 busiest examiner pending office action. This represents the only active prosecution for the company, placing significant importance on the examiner's specific feedback and requirements. Because the portfolio only interacts with 1 distinct art unit, the administrative burden is low, and the legal strategy can be tailored specifically to the standards of that unit.

The success of the company's current patent efforts rests on the resolution of the 1 pending office action under the guidance of BAILEY, STEVEN WILLIAM. Practitioners should focus on the examiner's specific technical background within Biotechnology & Pharmaceuticals to craft more persuasive responses. By addressing the 1 pending office action with a clear understanding of the 1 distinct art unit's expectations, the company can more efficiently navigate the prosecution process.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BAILEY, STEVEN WILLIAM 1 31.6% +15.2%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17245300 SYSTEMS AND METHODS FOR PERFORMING A GENOTYPE-BASED ANALYSIS OF AN INDIVIDUAL BAILEY, STEVEN WILLIAM 146d overdue

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17245300 SYSTEMS AND METHODS FOR PERFORMING A GENOTYPE-BASED ANALYSIS OF AN INDIVIDUAL BAILEY, STEVEN WILLIAM 146d overdue

Top Art Units

Art UnitApps
1687 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
17245300 SYSTEMS AND METHODS FOR PERFORMING A GENOTYPE-BASED ANALYSIS OF AN INDIVIDUAL BAILEY, STEVEN WILLIAM 1687 §101§103§112 Final Rejection 146d overdue Pending Apr 30, 2021

Managing The DNA Company Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does The DNA Company Inc. have?

The DNA Company Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most The DNA Company Inc. applications?

Steven William Bailey has the most, with 1 of The DNA Company Inc.'s pending office actions.

What technology area are The DNA Company Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month